The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ALKS 3831 (Alkermes) for the treatment of schizophrenia and bipolar I disorder. 

ALKS 3831 is composed of a novel molecular entity, samidorphan, a mu-opioid receptor antagonist, which is co-formulated with the established antipsychotic agent, olanzapine, in a single bilayer tablet. The investigational, once-daily oral formulation is designed to provide the efficacy of olanzapine while mitigating olanzapine-associated weight gain. 

The NDA is supported by data from the Enlighten clinical program, which includes two phase 3 studies. A total of 964 individuals diagnosed with schizophrenia participated. The Enlighten-1 study found that treatment with olanzapine/samidorphan resulted in significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) scores compared with placebo. The Enlighten-2 study found that olanzapine/samidorphan demonstrated both a lower mean percent weight gain from baseline at 6 months and a lower proportion of patients who gained 10% or more of their baseline body weight at 6 months compared with olanzapine alone (P =.003).

Related Articles

Alkermes is seeking approval of 4 fixed-dose strengths of olanzapine/samidorphan: 5mg/10mg, 10mg/10mg, 15mg/10mg and 20mg/10mg. A Prescription Drug User Fee Act (PDUFA) target action date of November 15, 2020 has been assigned to the application.

Continue Reading

For more information visit

This article originally appeared on MPR